A comparative clinical trial to test efficacy and safety of 2 brands of highly purified follicle-stimulating hormone in subjects undergoing IVF
- Conditions
- Infertility in female
- Registration Number
- CTRI/2010/091/000852
- Lead Sponsor
- Bharat Serums and Vaccines Limited
- Brief Summary
1. This study is a randomised open label multi-centre trial to compare the efficacy and safety of 2 brands of highly purified follicle-stimulating hormone in subjects undergoing their first cycle of invitro fertilization with intracytoplasmic sperm injection (ICSI). The study is being conducted at 5 centres in India. The primary outcomes are total number of eggs, total number of mature oocytes retrieved, no. of HP FSH vials used, total days of FSH stimulation. The secondary outcomes are number of embryos cleaved, clinical pregnancy rate, incidence of severe OHSS - Grade IV to VI and cancellation rate.
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Not specified
- Target Recruitment
- 100
- Subjects undergoing first cycle of invitro fertilization with Intracytoplasmic sperm injection (ICSI)2.
- Subjects aged >18 and <35 years 3.
- Normogonadotrophic subjects with normal FSH and LH levels4.
- Semen parameters compatible with Intracytoplasmic sperm injection (ICSI) 5.
- Hysterosalpingography or hysteroscopy documenting a uterus consistent with expected normal function 6.
- Transvaginal ultrasound documenting the presence of both ovaries, without evidence of abnormality.
- Subjects > 35 years of age.2. Infertility attributable to severe endometriosis (grade III or IV) 3.
- Subjects with previous failed IVF or IVF with ICSI cycle 4.
- Pelvic pathology that would compromise invitro fertilization (IVF) success5.
- Tumors and malformation of sexual organs incompatible with pregnancy 6.
- Hypersensitivity to any trial product.
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Total number of eggs 2. Total number of mature oocytes retrieved 3. No. of HP FSH vials used 4. Total days of FSH stimulation End of study - 6 weeks
- Secondary Outcome Measures
Name Time Method 1. Number of embryos cleaved 2. Clinical pregnancy rate 3. Incidence of severe OHSS - Grade IV to VI 4. Cancellation Rate End of study - 6 weeks
Trial Locations
- Locations (5)
Bavishi Fertility Institute
🇮🇳Ahmadabad, GUJARAT, India
Mandakini IVF Centre
🇮🇳Mumbai, MAHARASHTRA, India
Pulse Hospital
🇮🇳Ahmadabad, GUJARAT, India
Shanti Memorial Hospital
🇮🇳Udit, Nagar,, India
VAUNSHDHARA TEST TUBE BABY CENTRE
🇮🇳Nagpur, MAHARASHTRA, India
Bavishi Fertility Institute🇮🇳Ahmadabad, GUJARAT, IndiaDr. Himanshu BavishiPrincipal investigator07926574901drbavishi@ivfclinic.com